Log In
Print
BCIQ
Print
Print this Print this
 

Rifamycin SV MMX (CB-01-11)

  Manage Alerts
Collapse Summary General Information
Company Cosmo Pharmaceuticals S.A.
DescriptionBroad-spectrum, semisynthetic, oral non-absorbable antibiotic formulated with MMX multi-matrix system technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPhase III
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD); Treat travelers' diarrhea
Regulatory Designation

Partner

Dr. Falk Pharma GmbH


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today